Supernus Pharmaceuticals SUPN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$2.29M+80.6% | -$4.11M-127% | -$45.12M-217% | $22.5M+13.0% | -$11.83M-9,638% | ||
| $26.13M+28.2% | $25.02M+32.7% | $24.81M+23.4% | $21.36M+3.1% | $20.38M-1.8% | ||
| $8.48M+5.1% | $9.65M+26.5% | $7.83M+2.0% | $7.51M+14.6% | $8.07M+36.8% | ||
| $5.92M+248% | $19M+26,493% | -$2.65M+59.1% | -$7.16M+11.7% | -$3.99M+27.2% | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$5.62M-258% | $16.42M+593% | $7.13M+201% | -$4.81M-201% | $3.56M-0.4% | ||
| $105K+102% | $4.18M+231% | $12.94M+381% | -$4.89M+18.9% | -$4.73M-138% | ||
| $49K-98.8% | -$491K-17.5% | -$21.53M-82.0% | -$6.49M+49.3% | $3.94M-60.7% | ||
| $12.43M+269% | $6.91M-36.1% | $11.14M+536% | $2.5M— | -$7.37M-198% | ||
| -$284K+40.3% | —— | -$3.83M-127% | -$3.3M-14.6% | -$476K+72.3% | ||
| $21K+333% | —— | —— | —— | -$9K-500% | ||
| $2.26M+68.4% | —— | —— | —— | $1.34M-1.6% | ||
| $2.39M-68.8% | $17.76M— | $0+100% | $0+100% | $7.66M+800% | ||
| $66.52M+117% | $19.86M-55.3% | —— | $58.54M+64.3% | $30.6M-20.3% | ||
| $0-100% | $427K+100% | $129K-35.5% | $455K+611% | $327K+31.9% | ||
| $78.44M-33.8% | $90.2M-38.0% | $126.63M-43.7% | $140.56M+13.4% | $118.56M-38.8% | ||
| $59.22M-62.1% | $39.32M-70.4% | $468.56M+216% | $110.4M+46.3% | $156.2M+9.8% | ||
| -$19.22M-151% | —— | $48.71M+163% | —— | $37.32M+172% | ||
| $13.67M+569% | $8.56M+24.4% | $23.74M+586% | $3.28M+97.5% | $2.04M-29.8% | ||
| $4.56M+36.3% | $31K-96.9% | $811K+110% | $46K+4,500% | $3.34M+149% | ||
| $0-100% | $0— | $1.86M— | $2.3M— | $20.1M— | ||
| $9.12M+143% | $8.53M+44.8% | $21.07M+585% | $935K-43.6% | -$21.4M-1,463% | ||
| $56.42M+21.3% | —— | $8.11M+140% | $28.86M+355% | $46.52M+499% | ||
| -$412K-250% | $271K-97.9% | $3.08M-84.3% | $12.42M-39.2% | $274K-18.5% | ||
| $28.62M+1,904% | -$23.36M— | $3.54M— | $10.78M+36.6% | $1.43M-89.0% | ||
| $12.43M+269% | $6.91M-36.1% | $11.14M+536% | $2.5M— | -$7.37M-198% | ||
| $1.82M+232% | $698K-89.9% | —— | $920K-28.8% | $547K-25.1% | ||
| $192K-82.1% | —— | $921K+195% | $32K— | $1.07M+157% | ||
| $2.26M+68.4% | —— | —— | —— | $1.34M-1.6% | ||
| -$284K+40.3% | —— | -$3.83M-127% | -$3.3M-14.6% | -$476K+72.3% | ||
| $0-100% | —— | —— | —— | $4.9M— | ||
| $59.22M-62.1% | $39.32M-70.4% | $468.56M+216% | $110.4M+46.3% | $156.2M+9.8% | ||
| -$412K-250% | $271K-97.9% | $3.08M-84.3% | $12.42M-39.2% | $274K-18.5% | ||
| $66.52M+120% | $19.43M-56.0% | —— | $58.08M+63.3% | $30.27M-20.7% | ||
| $66.52M+120% | $19.43M-56.0% | —— | $58.08M+63.3% | $30.27M-20.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Supernus Pharmaceuticals generate?
- Supernus Pharmaceuticals (SUPN) generated $175.5M in operating cash flow over the trailing twelve months.
- What is Supernus Pharmaceuticals's free cash flow?
- After $1.0M of capital expenditures, Supernus Pharmaceuticals's free cash flow was $174.3M over the trailing twelve months, up 1.8% year over year.
- Where does Supernus Pharmaceuticals's cash flow data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
